
Senaparib Approved by NMPA for 1L Maintenance Therapy in Ovarian Cancer
SHANGHAI,Jan. 17,2025-- IMPACT Therapeutics ("IMPACT"),a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality